ReviewJournal of physiology and biochemistry2026
AMPK as a central regulator of necroptosis: mechanistic insights and therapeutic implications.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase that links cellular energy stress with metabolic adaptation, autophagy, redox homeostasis, and cell fate decisions. Necroptosis is a regulated lytic form of cell death driven by receptor-interacting serine/threonine kinases 1 and 3 (RIPK1 and RIPK3), with mixed lineage kinase domain-like protein (MLKL) serving as the terminal executor. Increasing evidence suggests that AMPK modulates necroptosis through multiple interconnected mechanisms. AMPK directly phosphorylates RIPK1, thereby influencing necroptotic signaling in a context- and time-dependent manner. Through the AMPK-mTOR axis, AMPK also regulates autophagy and mitophagy, affecting inhibitory control of RIPK1 and autophagic turnover of RIPK3. In parallel, AMPK suppresses necroptosis through SIRT1- and PGAM5-related pathways, limiting necrosome assembly, mitochondrial dysfunction, and Drp1-dependent mitochondrial fission. AMPK further shapes reactive oxygen species (ROS)-associated necroptotic responses through downstream effectors, including mTOR and Nrf2. In this review, we summarize recent advances in the mechanisms by which AMPK regulates necroptosis and highlight unresolved questions, including the cell-type-specific roles of AMPK subunits, the contribution of additional autophagy regulators, the balance between mTORC1-dependent protective signaling and RIPK3 stability, and the in vivo relevance of the AMPK-SIRT1-PGAM5 axis. Clarifying this regulatory network may facilitate the development of therapeutic strategies for necroptosis-related diseases, including metabolic disorders, ischemia-reperfusion injury, and neurodegeneration. Collectively, the available evidence indicates that AMPK acts as a context-dependent regulator of necroptosis rather than a universally protective kinase.
Indexed as
Identifiers
42584540What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.